Kristi Snell's most recent trade in Yield10 Bioscience Inc was a trade of 877 Common Stock done at an average price of $1.5 . Disclosure was reported to the exchange on Aug. 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Yield10 Bioscience Inc | Kristi Snell | VP Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.50 per share. | 15 Aug 2024 | 877 | 6,999 (0%) | 0% | 1.5 | 1,316 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research and CSO | Grant, award, or other acquisition of securities at price $ 0.30 per share. | 15 Feb 2024 | 120,000 | 129,022 (7%) | 6% | 0.3 | 36,000 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.59 per share. | 10 Feb 2023 | 1,177 | 9,022 (0%) | 0% | 3.6 | 4,225 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.68 per share. | 10 Aug 2022 | 988 | 10,199 (0%) | 0% | 2.7 | 2,648 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 01 Mar 2022 | 418 | 11,187 (0%) | 0% | 4.3 | 1,777 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 22,500 | 22,500 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Grant, award, or other acquisition of securities at price $ 3.83 per share. | 10 Feb 2022 | 6,733 | 11,605 (0%) | 0% | 3.8 | 25,787 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2021 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.71 per share. | 01 Sep 2021 | 351 | 4,872 (0%) | 0% | 6.7 | 2,355 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Grant, award, or other acquisition of securities at price $ 16.03 per share. | 01 Mar 2021 | 2,391 | 5,223 (0%) | 0% | 16.0 | 38,328 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.77 per share. | 11 Feb 2021 | 693 | 2,832 (0%) | 0% | 22.8 | 15,780 | Common Stock |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Kristi Snell | VP Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.55 per share. | 11 Aug 2020 | 587 | 3,525 (0%) | 0% | 6.6 | 3,845 | Common Stock |